EU guidance could jeopardise confidentiality, says industry, but consumers want more openness
This article was originally published in Scrip
Draft European guidance on the kind of information that can be released from drug approval dossiers has received a predictably mixed response from pharmaceutical industry and public interest bodies.
You may also be interested in...
New guidance from the UK covers the recognition of EU approvals, accelerated assessment, rolling reviews, and much else besides.
As negotiations between the UK and EU enter a crucial phase, the UK life sciences industry has called for more clarity and guidance on what companies can expect to face at the end of the Brexit transition period.
A legislative provision under which future COVID-19 vaccines can be made available in the UK before they are approved is also being used to offer an unlicensed flu vaccine that officials say has undergone full safety, efficacy and quality tests.